FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568001054> ?p ?o ?g. }

• W2568001054 endingPage "526" @default.
• W2568001054 startingPage "516" @default.
• W2568001054 abstract "Roflumilast is approved as an add-on therapy for chronic obstructive pulmonary disease. The inflammation in chronic obstructive pulmonary disease is mainly neutrophilic, while in asthma it is mainly eosinophilic, studies addressing role of roflumilast in eosinophilic inflammation are recommended. Also in severe asthma, the dominant inflammatory cells are neutrophils. Thus, roflumilast has a potential off-label use in the treatment of asthma. This study was designed to evaluate the effects of co-inhalation of roflumilast and fluticasone compared to that of formoterol and fluticasone in ovalbumin-sensitized and-challenged BALB/c mice. Besides normal control group, the ovalbumin-asthmatic mice were randomly divided into seven groups (n = 8): positive control, vehicle-treated, and five drug-treated groups. Treatments (µg/kg) were given as 15 min-inhalation once/day for five days as follows: roflumilast (500), formoterol (50), fluticasone (1000), roflumilast + fluticasone (500 + 1000), and formoterol + fluticasone (50 + 1000). Penh values were measured in conscious unrestrained mice using the single-chamber whole-body plethysmography. Airway hyperreactivity to inhaled methacholine was evaluated. Bronchoalveolar lavage fluid was used for the measurements of levels of IL-4, IL-5, TNF-α, OVA-specific IgE, and total and differential white cells. Lung sections were stained with hematoxylin and eosin and periodic acid-Schiff. The asthmatic mice showed significant increases in airway hyperreactivity which were significantly reversed by the combination treatments. The asthmatic mice showed significant increases in levels of IL-4, IL-5, TNF-α, ovalbumin-specific IgE, and total and differential white cells in bronchoalveolar lavage fluid. All treatments (except formoterol) significantly reversed these changes mainly with roflumilast + fluticasone. The asthmatic mice showed severe inflammatory infiltration and goblet cell hyperplasia which were maximally reversed by roflumilast + fluticasone, while minimally reversed by formoterol. In conclusion, co-inhalation of roflumilast + fluticasone more significantly improved inflammation and histopathological changes than co-inhalation of formoterol + fluticasone in ovalumin-asthmatic mice. Further studies are needed to help confirm the potential off-label add-on use of roflumilast in typical and atypical asthma and asthma-chronic obstructive pulmonary disease overlap syndrome. Impact statement Roflumilast, a selective phosphodiesterase-4 inhibitor, was approved for the treatment of chronic obstructive pulmonary disease (COPD). This study showed that co-inhalation of roflumilast and fluticasone significantly decreased airway hyperresponsiveness in ovalumin-asthmatic mice. Also, it more significantly improved inflammation and histopathological changes than co-inhalation of formoterol and fluticasone. The current results showed that inhaled roflumilast reduced counts of eosinophils, neutrophils, and macrophages in bronchoalveolar lavage fluid. Consequently, inhaled roflumilast might be of potential off-label benefit in treatment of eosinophilic and neutrophilic asthma and asthma-COPD overlap syndrome (ACOS). These results could also support other experimental and clinical studies addressing the same issue." @default.
• W2568001054 created "2017-01-13" @default.
• W2568001054 creator A5003560087 @default.
• W2568001054 creator A5014666094 @default.
• W2568001054 creator A5019193597 @default.
• W2568001054 creator A5019773537 @default.
• W2568001054 creator A5069663686 @default.
• W2568001054 creator A5078548781 @default.
• W2568001054 date "2017-01-05" @default.
• W2568001054 modified "2023-09-27" @default.
• W2568001054 title "Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice" @default.
• W2568001054 cites W1166909979 @default.
• W2568001054 cites W1488607683 @default.
• W2568001054 cites W1488731167 @default.
• W2568001054 cites W1714464098 @default.
• W2568001054 cites W1785644247 @default.
• W2568001054 cites W1934970325 @default.
• W2568001054 cites W1943574501 @default.
• W2568001054 cites W1954701421 @default.
• W2568001054 cites W1971574036 @default.
• W2568001054 cites W1971644509 @default.
• W2568001054 cites W1976993756 @default.
• W2568001054 cites W1985995428 @default.
• W2568001054 cites W1991119065 @default.
• W2568001054 cites W1993487040 @default.
• W2568001054 cites W1998761714 @default.
• W2568001054 cites W2004518103 @default.
• W2568001054 cites W2005808916 @default.
• W2568001054 cites W2016285965 @default.
• W2568001054 cites W2024940940 @default.
• W2568001054 cites W2029088640 @default.
• W2568001054 cites W2029347209 @default.
• W2568001054 cites W2029944874 @default.
• W2568001054 cites W2040080223 @default.
• W2568001054 cites W2041015076 @default.
• W2568001054 cites W2043907698 @default.
• W2568001054 cites W2045744166 @default.
• W2568001054 cites W2049610222 @default.
• W2568001054 cites W2062890064 @default.
• W2568001054 cites W2064522355 @default.
• W2568001054 cites W2071508654 @default.
• W2568001054 cites W2081338505 @default.
• W2568001054 cites W2092531447 @default.
• W2568001054 cites W2103368940 @default.
• W2568001054 cites W2106701404 @default.
• W2568001054 cites W2106724678 @default.
• W2568001054 cites W2121249725 @default.
• W2568001054 cites W2121459893 @default.
• W2568001054 cites W2125616834 @default.
• W2568001054 cites W2128790460 @default.
• W2568001054 cites W2128812998 @default.
• W2568001054 cites W2131055445 @default.
• W2568001054 cites W2132051696 @default.
• W2568001054 cites W2133912985 @default.
• W2568001054 cites W2134594508 @default.
• W2568001054 cites W2135728345 @default.
• W2568001054 cites W2136199835 @default.
• W2568001054 cites W2136612906 @default.
• W2568001054 cites W2137255331 @default.
• W2568001054 cites W2138050584 @default.
• W2568001054 cites W2139994262 @default.
• W2568001054 cites W2143812176 @default.
• W2568001054 cites W2144587984 @default.
• W2568001054 cites W2147138578 @default.
• W2568001054 cites W2149362097 @default.
• W2568001054 cites W2152333598 @default.
• W2568001054 cites W2152764690 @default.
• W2568001054 cites W2153231621 @default.
• W2568001054 cites W2154436876 @default.
• W2568001054 cites W2159262373 @default.
• W2568001054 cites W2162852294 @default.
• W2568001054 cites W2164371870 @default.
• W2568001054 cites W2167442442 @default.
• W2568001054 cites W2184248465 @default.
• W2568001054 cites W23179701 @default.
• W2568001054 cites W2397248706 @default.
• W2568001054 cites W2408680394 @default.
• W2568001054 cites W343309548 @default.
• W2568001054 cites W70489462 @default.
• W2568001054 doi "https://doi.org/10.1177/1535370216685006" @default.
• W2568001054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5367656" @default.
• W2568001054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28056550" @default.
• W2568001054 hasPublicationYear "2017" @default.
• W2568001054 type Work @default.
• W2568001054 sameAs 2568001054 @default.
• W2568001054 citedByCount "17" @default.
• W2568001054 countsByYear W25680010542017 @default.
• W2568001054 countsByYear W25680010542018 @default.
• W2568001054 countsByYear W25680010542019 @default.
• W2568001054 countsByYear W25680010542020 @default.
• W2568001054 countsByYear W25680010542021 @default.
• W2568001054 countsByYear W25680010542022 @default.
• W2568001054 countsByYear W25680010542023 @default.
• W2568001054 crossrefType "journal-article" @default.
• W2568001054 hasAuthorship W2568001054A5003560087 @default.
• W2568001054 hasAuthorship W2568001054A5014666094 @default.
• W2568001054 hasAuthorship W2568001054A5019193597 @default.
• W2568001054 hasAuthorship W2568001054A5019773537 @default.

• next